Article ID Journal Published Year Pages File Type
2811096 Trends in Endocrinology & Metabolism 2006 7 Pages PDF
Abstract

In patients with progressive metastatic (or recurrent) differentiated thyroid carcinoma that either do not take up radioioidine or are unresponsive to continued radioiodine therapy, staging is difficult and treatment options are few. However, in most of these patients uptake of radiolabeled somatostatin analogs is evident on somatostatin-receptor scintigraphy (SRS). Using SRS, patients with sufficient uptake of radiolabeled somatostatin analogs can be selected for high-dose peptide receptor radionuclide therapy (PRRT) as an alternative targeted-treatment option. PRRT with the β-particle-emitting radionuclides 90yttrium (90Y) and 177lutetium (177Lu) gives the best results in terms of objective tumor response. Promising, novel, radiolabeled somatostatin analogs that have a broader receptor affinity profile and, thus, a potentially wider therapeutic range are being tested clinically.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Endocrinology
Authors
, , ,